| Published Application/Species/Sample/Dilution | Reference |
|---|
- immunohistochemistry - paraffin section; human; 1:1000; fig 5d
- western blot; human; 1:20,000; loading ...; fig 3a
| Destouches D, Sader M, Terry S, Marchand C, Maillé P, Soyeux P, et al. Implication of NPM1 phosphorylation and preclinical evaluation of the nucleoprotein antagonist N6L in prostate cancer. Oncotarget. 2016;7:69397-69411 pubmed publisher |
- immunocytochemistry; human; fig 2a
| Liu X, Chen X, Rycaj K, Chao H, Deng Q, Jeter C, et al. Systematic dissection of phenotypic, functional, and tumorigenic heterogeneity of human prostate cancer cells. Oncotarget. 2015;6:23959-86 pubmed |
- immunohistochemistry - paraffin section; mouse; fig 1b
| Li H, Mohamed A, Sharad S, Umeda E, Song Y, Young D, et al. Silencing of PMEPA1 accelerates the growth of prostate cancer cells through AR, NEDD4 and PTEN. Oncotarget. 2015;6:15137-49 pubmed |
- immunohistochemistry - paraffin section; human; 0.2 ug/ml; fig 2
| Saffarini C, McDonnell Clark E, Amin A, Huse S, Boekelheide K. Developmental exposure to estrogen alters differentiation and epigenetic programming in a human fetal prostate xenograft model. PLoS ONE. 2015;10:e0122290 pubmed publisher |
| Asangani I, Dommeti V, Wang X, Malik R, Cieslik M, Yang R, et al. Therapeutic targeting of BET bromodomain proteins in castration-resistant prostate cancer. Nature. 2014;510:278-82 pubmed publisher |
| Yin Y, Xu L, Chang Y, Zeng T, Chen X, Wang A, et al. N-Myc promotes therapeutic resistance development of neuroendocrine prostate cancer by differentially regulating miR-421/ATM pathway. Mol Cancer. 2019;18:11 pubmed publisher |
| Li P, Chen J, Kashiwagi E, Mizushima T, Han B, Inoue S, et al. The interaction between androgen receptor and semenogelin I: a synthetic LxxLL peptide antagonist inhibits the growth of prostate cancer cells. Br J Cancer. 2017;: pubmed publisher |
| Unno K, Roh M, Yoo Y, Al Shraideh Y, Wang L, Nonn L, et al. Modeling African American prostate adenocarcinoma by inducing defined genetic alterations in organoids. Oncotarget. 2017;8:51264-51276 pubmed publisher |
| Chiang K, Tsui K, Chung L, Yeh C, Feng T, Chen W, et al. Cisplatin modulates B-cell translocation gene 2 to attenuate cell proliferation of prostate carcinoma cells in both p53-dependent and p53-independent pathways. Sci Rep. 2014;4:5511 pubmed publisher |
| Chiang K, Tsui K, Chung L, Yeh C, Chang P, Chen W, et al. Topoisomerase inhibitors modulate gene expression of B-cell translocation gene 2 and prostate specific antigen in prostate carcinoma cells. PLoS ONE. 2014;9:e89117 pubmed publisher |
| Duijvesz D, Burnum Johnson K, Gritsenko M, Hoogland A, Vredenbregt van den Berg M, Willemsen R, et al. Proteomic profiling of exosomes leads to the identification of novel biomarkers for prostate cancer. PLoS ONE. 2013;8:e82589 pubmed publisher |
| Vainio P, Mpindi J, Kohonen P, Fey V, Mirtti T, Alanen K, et al. High-throughput transcriptomic and RNAi analysis identifies AIM1, ERGIC1, TMED3 and TPX2 as potential drug targets in prostate cancer. PLoS ONE. 2012;7:e39801 pubmed publisher |
